Company intelligence / Profile preview
AIVITA Biomedical, Inc.
Irvine, California, United Statesaivitabiomedical.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Phase 2
01
Overview
Phase 2 glioblastoma trial showed improved progression-free survival by 50% compared to standard of care. The median length of PFS was 10.4 months versus 6.9 months in the landmark STUPP study. In a Phase 2 clinical trial for SARS-CoV-2 vaccine, they achieved 96% immune response. Previous melanoma trials demonstrated 72% 2-year survival and 54% 5-year survival.
- Therapeutic areas
- OphthalmologyOncologyInfectious Diseases
- Modalities
- Cell therapyPersonalized vaccinesStem cell applications
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
University of California at Irvine
Beyond the preview
Go deeper on AIVITA Biomedical, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIVITA Biomedical, Inc..